Orally active-targeted drug delivery systems for proteins and peptides

Expert Opinion on Drug Delivery

Volumn 11, Issue 9, 2014, Pages 1435-1447

  Li, Xiuying ^a   Yu, Miaorong ^a   Fan, Weiwei ^a   Gan, Yong ^a   Hovgaard, Lars ^b   Yang, Mingshi ^c  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Active targeted drug delivery systems; IgG Fc receptor; Intercellular adhesion molecule 1; Oral protein and peptide delivery; Proton coupled folate transporter; Recombinant fusion protein; Transferrin receptor

Indexed keywords

ALPHA GALACTOSIDASE; CALCITONIN; CHOLERA TOXIN B SUBUNIT; CYANOCOBALAMIN; CYANOCOBALAMIN PLUS GLUCAGON LIKE PEPTIDE 1; CYANOCOBALAMIN PLUS INSULIN; DEOXYCHOLIC ACID; DRUG CARRIER; EXENDIN 4; FOLIC ACID; IMMUNOGLOBULIN G; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; VACCINE; VITAMIN;

ACTIVE TRANSPORT; ANTIGEN ANTIBODY REACTION; CONJUGATE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; GOBLET CELL; HUMAN; INTESTINE CELL; MOLECULAR RECOGNITION; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

ACTIVE-TARGETED DRUG DELIVERY SYSTEMS; IGG-FC RECEPTOR; INTERCELLULAR ADHESION MOLECULE-1; ORAL PROTEIN AND PEPTIDE DELIVERY; PROTON-COUPLED FOLATE TRANSPORTER; RECOMBINANT FUSION PROTEIN; TRANSFERRIN RECEPTOR;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; PEPTIDES; PERMEABILITY; PROTEIN BINDING; PROTEINS;

EID: 84906316137     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.924500     Document Type: Review

References (88)

1. Maria Burke SW. Scrip Biopharmaceuticals: A new era of discovery in the biotechnology revolution?. PJB Publications, Richmond, UK; 2001. p. 257
2. Sonia TA, Sharma CP. An overview of natural polymers for oral insulin Delivery. Drug Discov Today 2012;17:784-92
3. Chen MC, Sonaje K, Chen KJ, Sung HW. A review of the prospects for polymeric nanoparticle platforms in oral insulin Delivery. Biomaterials 2011;32:9826-38
4. Fix JA. Oral controlled release technology for peptides: Status and future prospects. Pharm Res 1996;13:1760-4
5. Su FY, Lin KJ, Sonaje K, et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin Delivery. Biomaterials 2012;33:2801-11
6. Reix N, Parat A, Seyfritz E, et al. In vitro uptake evaluation in Caco-2 cells and in vivo results in Diabetic rats of insulin-loaded PLGA nanoparticles. Int J Pharm 2012;437:213-20
7. Plapied L, Duhem N, des Rieux A, Preat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface 2011;16:228-37
8. Mrsny RJ. Oral drug delivery research in Europe. J Control Release 2012;161:247-53
9. McNeela EA, Lavelle EC. Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination. Curr Top Microbiol Immunol 2012;354:75-99
10. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein Delivery. Adv Drug Deliv Rev 2013;65:822-32
11. Russell-Jones G. Intestinal receptor targeting for peptide delivery: An experts personal perspective on reasons for failure and new opportunities. Ther Deliv 2011;2:1575-93
12. Woodley JF. Enzymatic Barriers for Gi Peptide and Protein Delivery. Crit Rev Ther Drug Carrier Syst 1994;11:61-95
13. Ahn J, Cao MJ, Yu YQ, Engen JR. Accessing the reproducibility and specificity of pepsin and other aspartic proteases. Biochim Biophys Acta 2013;1834:1222-9
14. Ciechanover A. Intracellular protein Degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human Diseases and drug targeting. Biochim Biophys Acta 2012;1824:3-13
15. Oda K, Yumoto R, Nagai J, et al. Mechanism underlying insulin uptake in alveolar epithelial cell line RLE-6TN. Eur J Pharmacol 2011;672:62-9
16. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem 2003;278:50393-401
17. Norris DA, Sinko PJ. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polym Sci 1997;63:1481-92
18. Aoki Y, Morishita M, Takayama K. Role of the mucous/glycocalyx layers in insulin permeation across the rat ileal membrane. Int J Pharm 2005;297:98-109
19. Tomita M, Shiga M, Hayashi M, Awazu S. Enhancement of colonic drug absorption by the paracellular permeation route. Pharm Res 1988;5:341-6
20. Rubas W, Cromwell ME, Shahrokh Z, et al. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 1996;85:165-9
21. Pappenheimer JR. Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J Membr Biol 1987;100:137-48
22. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004;12:65-70
23. Burton PS, Conradi RA, Hilgers AR. (B) Mechanisms of peptide and protein absorption: (2) Transcellular mechanism of peptide and protein absorption: Passive aspects. Adv Drug Deliv Rev 1991;7:365-85
24. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: Methods and studies. Fundam Clin Pharmacol 1999;13:154-68
25. Bai JP, Amidon GL. Structural specificity of mucosal-cell transport and metabolism of peptide drugs - implication for oral peptide drug delivery. Pharm Res 1992;9:969-78
26. Swaan PW. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm Res 1998;15:826-34
27. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: Barriers and developments. BioDrugs 2005;19:165-77
28. Clardy SM, Allis DG, Fairchild TJ, Doyle RP. Vitamin B12 in Drug delivery: Breaking through the barriers to a B12 bioconjugate pharmaceutical. Expert Opin Drug Deliv 2011;8:127-40
29. Zhao RB, Diop-Bove N, Visentin M, Goldman ID. Mechanisms of Membrane Transport of Folates into Cells and Across Epithelia. Annu Rev Nutr 2011;31:177-201
30. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28
31. Said HM. Cell and molecular aspects of human intestinal biotin absorption. J Nutr 2009;139:158-62
32. Balamurugan K, Ortiz A, Said HM. Biotin uptake by human intestinal and liver epithelial cells: Role of the SMVT system. Am J Physiol Gastrointest Liver Physiol 2003;285:G73-7
33. Balamurugan K, Said HM. Functional role of specific amino acid residues in human thiamine transporter SLC19A2: Mutational analysis. Am J Physiol Gastrointest Liver Physiol 2002;283:G37-43
34. Widera A, Norouziyan F, Shen WC. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev 2003;55:1439-66
35. Papademetriou IT, Garnacho C, Schuchman EH, Muro S. In vivo performance of polymer nanocarriers dually-Targeted to epitopes of the same or different receptors. Biomaterials 2013;34:3459-66
36. He W, Ladinsky MS, Huey-Tubman KE, et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography. Nature 2008;455:542-6
37. Parkos CA, Colgan SP, Diamond MS, et al. Expression and polarization of intercellular adhesion molecule-1 on human intestinal epithelia: Consequences for CD11b/CD18-mediated interactions with neutrophils. Mol Med 1996;2:489-505
38. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: An overview. Adv Drug Deliv Rev 2013;65:1340-56
39. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002;64:635-61
40. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 2004;56:491-509
41. Gabor F, Schwarzbauer A, Wirth M. Lectin-mediated drug delivery: Binding and uptake of BSA-WGA conjugates using the Caco-2 model. Int J Pharm 2002;237:227-39
42. Holmgren J, Lonnroth I, Mansson J, Svennerholm L. Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci USA 1975;72:2520-4
43. Kang SK, Woo JH, Kim MK, et al. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J Biotechnol 2008;135:210-16
44. Baum LG, Paulson JC. Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem Suppl 1990;40:35-8
45. Nikitas G, Deschamps C, Disson O, et al. Transcytosis of Listeria monocytogenes across the intestinal barrier upon specific targeting of goblet cell accessible E-cadherin. J Exp Med 2011;208:2263-77
46. Gupta PN, Vyas SP. Investigation of lectinized liposomes as M-cell targeted carrier-Adjuvant for mucosal immunization. Colloid Surf B Biointerfaces 2011;82:118-25
47. Gullberg E, Leonard M, Karlsson J, et al. Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem Biophys Res Commun 2000;279:808-13
48. Hamzaoui N, Kerneis S, Caliot E, Pringault E. Expression and distribution of beta 1 integrins in in vitro-induced M cells: Implications for Yersinia adhesion to Peyers patch epithelium. Cell Microbiol 2004;6:817-28
49. Ezpeleta I, Arangoa MA, Irache JM, et al. Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm 1999;191:25-32
50. Al-Hilal TA, Alam F, Byun Y. Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Deliv Rev 2013;65:845-64
51. Petrus AK, Allis DG, Smith RP, et al. Exploring the implications of vitamin B12 conjugation to insulin on insulin receptor binding. ChemMedChem 2009;4:421-6
52. Clardy-James S, Chepurny OG, Leech CA, et al. Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagonlike peptide-1. ChemMedChem 2013;8:582-6
53. Fazen CH, Valentin D, Fairchild TJ, Doyle RP. Oral delivery of the appetite suppressing peptide hPYY(3-36) through the vitamin B12 uptake pathway. J Med Chem 2011;54:8707-11
54. Youn YS, Chae SY, Lee S, et al. Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: Design, preparation, and biological evaluation. Eur J Pharm Biopharm 2008;68:667-75
55. Chae SY, Jin CH, Shin HJ, et al. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug Chem 2008;19:334-41
56. Kavimandan NJ, Losi E, Peppas NA. Novel delivery system based on complexation hydrogels as delivery vehicles for insulin-Transferrin conjugates. Biomaterials 2006;27:3846-54
57. Kavimandan NJ, Losi E, Wilson JJ, et al. Synthesis and characterization of insulin-Transferrin conjugates. Bioconjug Chem 2006;17:1376-84
58. Xia CQ, Wang J, Shen WC. Hypoglycemic effect of insulin-Transferrin conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2000;295:594-600
59. Shofner JP, Phillips MA, Peppas NA. Cellular evaluation of synthesized insulin/ transferrin bioconjugates for oral insulin Delivery using intelligent complexation hydrogels. Macromol Biosci 2010;10:299-306
60. Al-Hilal TA, Park J, Alam F, et al. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. J Control Release 2014;175:17-24
61. Amet N, Wang W, Shen WC. Human growth hormone-Transferrin fusion protein for oral delivery in hypophysectomized rats. J Control Release 2010;141:177-82
62. Bobst CE, Wang SH, Shen WC, Kaltashov IA. Mass spectrometry study of a transferrin-based protein Drug reveals the key role of protein aggregation for successful oral delivery. Proc Natl Acad Sci USA 2012;109:13544-8
63. Vallee S, Rakhe S, Reidy T, et al. Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res 2012;32:178-84
64. Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal Fc receptormediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci USA 2012;109:16095-100
65. Ying T, Chen W, Feng Y, et al. Engineered soluble monomeric IgG1 CH3 domain: Generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288:25154-64
66. Chunfeng G, Xiaozhou L, Gang W, et al. Expression of cholera toxin Blumbrokinase fusion protein in Pichia pastoris-The use of transmucosal carriers in the delivery of therapeutic proteins to protect rats against thrombosis. Appl Biochem Biotechnol 2013;169:636-50
67. Kwon KC, Nityanandam R, New JS, Daniell H. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J 2013;11:77-86
68. Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007;117:421-9
69. Chalasani KB, Russell-Jones GJ, Jain AK, et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007;122:141-50
70. Zhang XW, Qi JP, Lu Y, et al. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 2014;10:167-76
71. Yang SJ, Lin FH, Tsai KC, et al. Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells. Bioconjug Chem 2010;21:679-89
72. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm 2012;9:2103-10
73. Ling SS, Yuen KH, Magosso E, Barker SA. Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats. J Pharm Pharmacol 2009;61:445-9
74. Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 2014;15:350-60
75. Jain S, Rathi VV, Jain AK, et al. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Nanomedicine (Lond) 2012;7:1311-37
76. Du WW, Fan YC, Zheng N, et al. Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery. Biomaterials 2013;34:794-806
77. Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8:137-43
78. Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-Targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 2013;5:213ra167
79. Muro S, Garnacho C, Champion JA, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-Targeted carriers. Mol Ther 2008;16:1450-8
80. Ghaffarian R, Bhowmick T, Muro S. Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1. J Control Release 2012;163:25-33
81. Makhlof A, Fujimoto S, Tozuka Y, Takeuchi H. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm 2011;77:216-24
82. Zhang N, Ping QN, Huang GH, Xu WF. Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int J Pharm 2005;294:247-59
83. Zhang N, Ping QN, Huang GH, et al. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006;327:153-9
84. Jin Y, Song Y, Zhu X, et al. Goblet cell-Targeting nanoparticles for oral insulin Delivery and the influence of mucus on insulin transport. Biomaterials 2012;33:1573-82
85. Zhang J, Zhu X, Jin Y, et al. Mechanism study of cellular uptake and tight junctions opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol Pharm 2014. [Epub ahead of print
86. Rajapaksa TE, Stover-Hamer M, Fernandez X, et al. Claudin 4-Targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2010;142:196-205
87. Kunisawa J, Kurashima Y, Kiyono H. Gut-Associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev 2012;64:523-30
88. Jiang T, Singh B, Li HS, et al. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014;35:2365-73.